Alzheimer’s disease (AD) is characterized by deposition of amyloid-β protein aggregates and an appropriate treatment strategy is urgently needed, as the number of diagnosed cases continues to increase. The management of AD and other brain-associated diseases is limited by the blood brain barrier and its selective control of drug passage. In fact, most of the promising drugs have restricted curative effects on AD owing to their lower bioavailability. Gold nanoparticles (AuNPs) have emerged as attractive therapeutic agents and have distinctive properties that could contribute to the development of a novel treatment strategy for neurodegenerative disorders. In this review article, we attempt to identify promising ways of developing competent AD therapeutic agents from anti-amyloid aggregating AuNPs. Initially, we discuss the current status of anti-amyloid inhibitors, the abilities of AuNPs to inhibit amyloid aggregation, and mechanistic aspects, and then describe plausible modifications that could aid the translation of AuNP-based therapeutics into neuromedicines. The review highlights some interesting characteristics that might effectively bridge the gap between laboratory and bedside treatments.

阿尔茨海默氏病（AD）的特征在于淀粉样β蛋白聚集体的沉积，并且随着诊断病例数的不断增加，迫切需要一种适当的治疗策略。AD和其他与脑相关的疾病的治疗受到血脑屏障及其对药物通过的选择性控制的限制。实际上，大多数有前途的药物由于其生物利用度较低而对AD的疗效有限。金纳米颗粒（AuNPs）已成为有吸引力的治疗剂，并具有独特的特性，可促进神经退行性疾病的新型治疗策略的发展。在这篇综述文章中，我们尝试确定从抗淀粉样蛋白聚集的AuNPs开发有效的AD治疗药物的有前途的方法。原来，我们讨论了抗淀粉样蛋白抑制剂的现状，AuNPs抑制淀粉样蛋白聚集的能力以及机制方面，然后描述了可能有助于将基于AuNP的治疗药物转化为神经医学的合理修饰。该评论强调了一些有趣的特征，这些特征可能有效地弥合了实验室和床头治疗之间的差距。